Pronova BioPharma to Construct a New Manufacturing Facility in Kalundborg

Pronova BioPharma ASA has announced the approval from the board to start construction of a new manufacturing facility to be located in Kalundborg, Denmark. The new facility is expected to double the current production capacity of the active pharmaceutical ingredient, API, used in Pronova BioPharma's lead product, marketed as Omacor in Europe and Lovaza in the United States.

Pronova BioPharma has experienced strong growth over the past three years and the need for a second manufacturing site has been driven by continued increases in demand for the company's API. The company believes the new site is ideally located within the pharmaceutical development cluster in Denmark, and is expected to provide Pronova BioPharma access to highly qualified and skilled employees.

For further information please contact:

Solveig Hellebust,

Vice President HR & Communications

Tel: +47 22 53 48 94

Email: solveig.hellebust@pronova.com

Or visit:www.pronova.com